LABT Lakewood-Amedex Biotherapeutics Inc.

-

Lakewood-Amedex Biotherapeutics Missed Consensus Estimates

Thursday, August 13, 2026 · 12:00 AM ET

Lakewood-Amedex Biotherapeutics (LABT) reported a loss of $2.75 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus earnings estimate was $0.65 per share. The company missed consensus estimates by 523.08%.

Earnings Whisper Grade
Power Rating
Reported Earnings
($2.75)
Earnings Whisper®
Consensus Estimate
$0.65
Earnings Surprise
Earnings Growth
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth